Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
LAEKNA-B (02105.HK) announced that it intends to place a total of 17.636 million shares of the company, equivalent to about 4 ...
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
Bengaluru: Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...
LAEKNA-B (02105.HK) -0.580 (-3.737%) announced a share placing immediately after a 48% share surge yesterday (20th). Today ...
(Reuters) - Eli Lilly (LLY) and Hong Kong-listed Laekna (2105.HK) will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.